<DOC>
	<DOCNO>NCT00356720</DOCNO>
	<brief_summary>To assess child efficacy safety 2 dosing regimen T1225 1.5 % eye drop , comparison reference product , single-dose oral azithromycin ( AZM ) 20 mg/kg , treatment active trachoma . Evaluation clinical efficacy primary ( % clinical cure Day 60 Per Protocol Set ) , microbiological evaluation secondary</brief_summary>
	<brief_title>Efficacy Safety 2 Dosing Regimens T1225 Eye Drops 1.5 % Versus Oral Azithromycin Treatment Trachoma</brief_title>
	<detailed_description>The aim present study compare efficacy dose regimen demonstrate pharmacokinetic study best candidate trachoma treatment ( T1225 1.5 % eye drop BID 3 day ) short duration treatment ( T1225 1.5 % eye drop BID 2 day ) single oral administration AZM ( 20 mg/kg ) patient suffer active trachoma . The study perform approximately 600 child ( age 1 10 year ) Guinea Conakry Pakistan .</detailed_description>
	<mesh_term>Trachoma</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male female age 110 year ; write informed consent legally acceptable representative ; TF+ TI0 ( trachomatous inflammation – follicular ) TF+TI+ ( trachomatous inflammation – follicular intense ) simplify World Health Organisation ( WHO ) grade system Trichiasis corneal opacity ; palpebral deformation ; clinically significant ocular abnormality ; ocular infection ; organic amblyopia ; hypersensitivity treatment ' component ; immunosuppressive condition ; systemic AZM steroid ; topical ophthalmic antibiotic within 3 month ; systemic antibiotic within 1 month ; topical ( ocular , nasal , bronchial etc . ) treatment within 1 week ; systemic nonsteroidal antiinflammatory drug day Day 0</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>